


# Production of radionuclides for medical applications

**F. Haddad**  
Université de Nantes  
Subatech / GIP Arronax

# Let's start with some nuclear physics

A nucleus is characterized by: **Z** (number of protons)


**N** (number of neutrons).



Two nuclei having the same **Z** but a different **A=N+Z** are **isotopes**

**They have the same chemical properties**

# Available radiation from radioactive decay




After a radioactive decay, a nucleus is often in an excited state.

The electron cloud of the atom is often disrupted

# Chart of nuclides

Nuclear medicine uses the interaction properties of these radiation with matter.

- *Highly penetrating* radiation are used **for imaging and diagnosis** ( $X, \gamma, \beta^+$ )
- *Low penetrating* radiation are used for **therapy** ( $\alpha, \beta^-, e\text{-Auger}$ )



How can we get radionuclides for medical applications?


# Some are available in our environment

Some radioisotopes are created by interaction of cosmic rays with the atmosphere ( $^{14}\text{C}$ ,  $^3\text{H}$ ,  $^7\text{Be}$ ,  $^{39}\text{Ar}$ ,...).

→ None are useful for medical applications

Radionuclides from decay chain of long lived radioisotopes


→ Few are used for medical applications




$^{223}\text{Ra}$ : Belongs to the  $^{235}\text{U}$  decay chain.  
Xofigo ( $\text{RaCl}_2$ ) used for bone metastases treatment.




$^{212}\text{Pb}/^{212}\text{Bi}$ : Belongs to the  $^{232}\text{Th}$  decay chain  
Clinical trial underway in breast cancer.



# Most of the radionuclides are artificially created




# Most of the radionuclides are artificially created









# Artificially Induced Radioactivity



Charge and mass conservation are mandatory


Many different nuclear reactions can be used:



As well as energy conservation

→ A **threshold projectile kinetic energy** exist in many cases

# Nuclear reaction



Better if we start from stable material as target material

# Production yield: use of thick target

Irradiation conditions

Reaction  
Cross section

Produced  
Activity:

$$\text{Act} = \Phi \cdot \chi \cdot \frac{\text{Na} \cdot \rho}{A} \cdot (1 - \exp(-\lambda \cdot t_{\text{irr}})) \cdot \int_{E_{\text{fn.}}}^{E_{\text{in.}}} \frac{\sigma(E)}{dx} \cdot dE$$

Target characteristics  
including enrichment

Radioactive decay


Decrease of the  
projectile energy as it  
penetrates into the  
target material

- Energy is released in the target
- Heating of the target

# How to increase the production yield?

- ✓ Increase the irradiation time
- ✓ Increase projectile number



Production of  $^{18}\text{F}$ -aq via  $^{18}\text{O}(p,n)^{18}\text{F}$   
1.3ml Titaniumtarget



Activity measured in a lead box after transfer over 40m through a 0.8mm tube

# How to increase the production yield?

- ✓ Increase the irradiation time
- ✓ Increase projectile number



## Limitations:

- Irradiation time  $< T_{1/2}$
- Integrity of the target due to heating

# How to increase the production yield?

- ✓ Increase the irradiation time
  
- ✓ Increase projectile number
  
- ✓ Increase target quantity:
  - Target thickness
  - Use of enriched material

# How to increase the production yield?

✓ Increase the irradiation time

✓ Increase projectile number

✓ Increase target quantity:

- Target thickness
- Use of enriched material

## Limitations:

- Integrity of the target due to heating
- Price of the target  $^{64}\text{Ni}$  is 30\$/mg  
Gold is 36.58€/g
- Target preparation:

# Target preparation

## Selection of the target material chemical form:



2 possibilities: RbCl or Rb metal


Rb metal:

Better yield

Better thermal conductivity

→ Higher beam current on target

Far more reactive than RbCl





# Target preparation

## Selection of the target material chemical form:



2 possibilities: RbCl or Rb metal


Rb metal:

Better yield


Better thermal conductivity

→ Higher beam current on target


Far more reactive than RbCl



## How to produce the target: Solid Targets



Electroplating  
Ni onto Au



Deposition under vacuum  
Bi onto Al




Pelletizing  
CaCO<sub>3</sub>



# Target preparation

## How to produce the target: Liquid and gas targets

H<sub>2</sub>O for <sup>18</sup>F




<sup>124</sup>Xe  
for <sup>123</sup>I




# How to increase the production yield?

- ✓ Increase the irradiation time
- ✓ Increase projectile number
- ✓ Increase target quantity
- ✓ Use of enriched material
- ✓ Carefully select the nuclear reaction and the projectile energy.



# Carrefully select the nuclear reaction and the projectile energy.



By a smart choice of the incident energy and target thickness, one can:

Maximizes the production yield

Minimizes the production of contaminants.


# Comparing production route for $^{124}\text{I}$

(calculated values – *Qaim et al - Julich*)

Nuclear reaction	Energy range [MeV]	Thick target yield of $^{124}\text{I}$ [MBq/ $\mu\text{A}\cdot\text{h}$ ]	Impurity [%]		
			$^{123}\text{I}$	$^{125}\text{I}$	$^{126}\text{I}$
$^{124}\text{Te}(\mathbf{p},\mathbf{n})$	12 → 8	16	1.0	< 0.1	-
$^{124}\text{Te}(\mathbf{d},\mathbf{2n})$	14 → 10	17.5	-	1.7	-
$^{125}\text{Te}(\mathbf{p},\mathbf{2n})$	21 → 15	81	7.4	0.9	-
$^{126}\text{Te}(\mathbf{p},\mathbf{3n})$	38 → 28	222	149	1.	1.
$^{\text{nat}}\text{Sb}(\alpha,\mathbf{xn})$	22 → 13	1.02	890	13	16
$^{\text{nat}}\text{Sb}(\mathbf{^3He},\mathbf{xn})$	35 → 13	0.95	3877	0.6	0.6

- $^{124}\text{Te}(\mathbf{p},\mathbf{n})^{124}\text{I}$  – purest  $^{124}\text{I}$
- $^{126}\text{Te}(\mathbf{p},\mathbf{3n})^{124}\text{I}$  – greatest production quantity

# Most of the radionuclides are artificially created




# Extraction and Purification step


**Wet chemistry**  
(chromatography using resin,  
liquid liquid separation, ...)



**Dry chemistry**





**Mass separation:**




# $^{64}\text{Cu}$ – PET imaging

$T_{1/2} = 12,7 \text{ h}$



Proton energy range  
12-10 MeV

Enriched Ni-64 target  
obtained through  
electroplating on a gold  
support



$e = 20 \mu\text{m}$   
 $S = 1.3 \text{ cm}^2$




# Extraction and Purification step

## Main impurities:

- $^{61}\text{Co}$  produced via the (p, $\alpha$ ) but also traces of other cobalt isotopes ( $^{55}\text{Co}$ ,  $^{56}\text{Co}$ ,  $^{57}\text{Co}$ ).
- Recovery of expensive  $^{64}\text{Ni}$  needed

**Extraction separation:** dissolution in  $\text{HNO}_3$  then use of AG1x8 resin.

elution profile of the irradiated target





# an example of dry chemistry: $^{211}\text{At}$



Nuclear reaction:



Bismuth target on its AlN backing



Dry extraction device




Astatine starts to get out after few minutes and the total processing time is around 2h

Extraction yield > 80 %


# High purity radioisotopes - Mass separation

## Production and Separation of $^{153}\text{Sm}$

Production of  $^{153}\text{Sm}$ :




Separation/Purification of  $^{153}\text{Sm}$  from target material using magnetic mass separator.




Dr. John D'Auria IsoTherapeutics Group LLC and Simon Fraser University

# Development of a radiopharmaceutical



## Medical validation



## Radiopharmaceutical

## Radiopharmacy Step Radiolabeling




## Radiochemistry Step Extraction and Purification

# Radionuclide of interest for PET

## Main positron emitters

Oxygen-15	2mn
Nitrogen-13	10 mn
Carbon-11	20mn
Fluorine-18	110mn



The most used one is  $^{18}\text{F}$  with *Fluorodeoxyglucose*

Other can be selected with respect to:

- $T_{1/2}$  → to adapt to vector transit time
- branching ratio → to optimize the contrast on the image
- associated radiation → potential radioprotection issues
- positron energy → to get the best image resolution
- Generator produced,... → to reduce logistics

Sc-44, Cu-64, Zr-89, I-124, Tb-152, ...

# Radionuclide of interest for PET : $^{89}\text{Zr}$

$9/2+$  ———  $0.0$   $78.41$  H 12

$^{89}\text{Zr}_{49}$

$Q(\text{gs})=2833.0$  keV 28

$\epsilon : 100\%$

$\beta^+ : 22.74\%$

$\langle E \rangle = 396$  keV

$I(\%)$   $\text{Logft}$

$0.745$   $6.18$   
 $0.073$   $7.53$

$9/2+$  ———  $2622.2$   
 $7/2+$  ———  $2530$

$1620.8$

$1713$

$I(\%)$   $\text{Logft}$

$0.106$   $7.25$

$11/2+$

$1657.3$

$2566.5$

$0.123$   $9.09$

$5/2-$

$1744.5$

$1744.5$

$98.95$   $6.152$

$9/2+$

$909.2$

$909.2$

$1/2-$

$0$

STABLE




$^{89}\text{Y}_{50}$

Pour  $^{18}\text{F}$ :  $\beta^+ : 96.73\%$

$\langle E \rangle = 249.8$  keV



# An example of the Added value of PET nodule in the prostate



## An antibody coupled to Zr-89

Nodule diameter <1cm

→ No suspicion in CT Scan

PET exam shows the nodule uptake is high

→ cancerous





# Rubidium-82 ( $^{82}\text{Rb}$ )

PET imaging in cardiology


An exemple of PET production using a solid target



# Rubidium-82 ( $^{82}\text{Rb}$ ): PET imaging in cardiology



# Rubidium-82 ( $^{82}\text{Rb}$ ): PET imaging in cardiology



*D. Le Guludec et al, Eur J Nucl Med Mol Imaging 2008; 35: 1709-24*


## Several advantages:

Better corrections

Quantification



Shorter duration of the exam

Lower dose to patient




**$^{82}\text{Sr}/^{82}\text{Rb}$  generator**

# Rubidium-82 ( $^{82}\text{Rb}$ ): PET imaging in cardiology





# Rubidium-82 ( $^{82}\text{Rb}$ ): PET imaging in cardiology



T = PET Scanner

S = NaCl solution

G = Chart containing the Sr82/Rb82 generator

D = Automatic infusion system

C = Control computer





Generator  $^{82}\text{Sr}/^{82}\text{Rb}$



Infusion system

# $^{82}\text{Sr}$ production

## Reaction and Cross section



Low cross section

Energy range of  
interest  
40 MeV-70 MeV

**Production needs high energy machines and high intensity beams**




# ARRONAX irradiation station

**Pressed pellet of  
RbCl**




**Encapsulated  
RbCl**



Rabbit



# RbCl inventory (simulation using MCNPX)



# Extraction and purification

Irradiation dans un  
Cyclotron de la  
pastille de  $\text{RbCl}$   
 $^{85}\text{Rb}(p,4n)$   $^{82}\text{Sr}$

Résine de séparation  
Purification de Sr



Good separation


Reproducibility verified

Extraction yield =  $92.9\% \pm 3.7\%$  ( $k=2$ )

Purity of the product fulfills regulatory requirements.




# Processing in hot cells




Hot cells

Dismounting the rabbit




# Processing in hot cells

RbCl target  
opening in hot  
cells




# Processing in hot cells



Chemical separation



# Dispensing and quality control



## Quality control:

- $\gamma$  -Spectroscopy
- ICP-OES

## Shipment



# Conclusions

- ⌘ Many different constraints have to be taken into account to develop radionuclide production
- ⌘ The weight to put on different parameters depends on the application
- ⌘ These rules are the same for therapeutic radionuclides
- ⌘ Medical applications drive the field neither physics nor chemistry.
- ⌘ Exciting fields with new techniques and new isotopes

# Thank you for your attention

The **ARRONAX** project is supported by:  
the **Regional Council of Pays de la Loire**  
the **Université de Nantes**  
the **French government (CNRS, INSERM)**  
the **European Union.**

This work has been, in part, supported by a grant from the French National Agency for Research called "Investissements d'Avenir", Equipex Arronax-Plus noANR-11-EQPX-0004 and Labex IRON noANR-11-LABX-18-01